Concepts (347)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognition | 49 | 2023 | 948 | 8.560 |
Why?
|
| Brain | 40 | 2023 | 1203 | 5.320 |
Why?
|
| Aging | 36 | 2023 | 1102 | 5.090 |
Why?
|
| White Matter | 11 | 2022 | 107 | 4.570 |
Why?
|
| Cognitive Dysfunction | 32 | 2023 | 737 | 4.390 |
Why?
|
| Alzheimer Disease | 30 | 2023 | 1320 | 4.070 |
Why?
|
| Aged | 118 | 2023 | 7447 | 3.990 |
Why?
|
| Neuropsychological Tests | 61 | 2023 | 865 | 3.660 |
Why?
|
| Cardiovascular Diseases | 13 | 2023 | 290 | 3.310 |
Why?
|
| Cognition Disorders | 19 | 2020 | 692 | 3.070 |
Why?
|
| Magnetic Resonance Imaging | 38 | 2023 | 860 | 2.990 |
Why?
|
| Humans | 147 | 2023 | 22947 | 2.810 |
Why?
|
| Female | 103 | 2023 | 12954 | 2.690 |
Why?
|
| Male | 100 | 2023 | 12458 | 2.660 |
Why?
|
| Diffusion Tensor Imaging | 12 | 2023 | 48 | 2.640 |
Why?
|
| Hypertension | 7 | 2022 | 163 | 2.360 |
Why?
|
| Depression | 8 | 2020 | 368 | 2.240 |
Why?
|
| Middle Aged | 72 | 2023 | 7910 | 2.180 |
Why?
|
| Executive Function | 21 | 2023 | 89 | 2.080 |
Why?
|
| Aged, 80 and over | 55 | 2023 | 3728 | 2.040 |
Why?
|
| Blood Pressure | 8 | 2022 | 166 | 1.900 |
Why?
|
| Dementia | 16 | 2023 | 388 | 1.880 |
Why?
|
| Verbal Learning | 11 | 2021 | 25 | 1.730 |
Why?
|
| Memory Disorders | 7 | 2018 | 108 | 1.710 |
Why?
|
| Diet, Mediterranean | 5 | 2023 | 63 | 1.690 |
Why?
|
| Acculturation | 3 | 2023 | 22 | 1.650 |
Why?
|
| Memory, Short-Term | 11 | 2023 | 79 | 1.630 |
Why?
|
| Risk Factors | 26 | 2023 | 1970 | 1.620 |
Why?
|
| Connectome | 5 | 2021 | 10 | 1.600 |
Why?
|
| Prefrontal Cortex | 7 | 2016 | 103 | 1.500 |
Why?
|
| Gray Matter | 5 | 2023 | 39 | 1.490 |
Why?
|
| Neuroimaging | 10 | 2023 | 100 | 1.440 |
Why?
|
| Health Literacy | 3 | 2023 | 84 | 1.400 |
Why?
|
| Cerebrovascular Disorders | 4 | 2021 | 99 | 1.340 |
Why?
|
| Residence Characteristics | 4 | 2021 | 171 | 1.290 |
Why?
|
| Decision Making | 6 | 2023 | 176 | 1.240 |
Why?
|
| Arteriolosclerosis | 3 | 2023 | 57 | 1.140 |
Why?
|
| Brain Mapping | 10 | 2021 | 123 | 1.140 |
Why?
|
| Public Health | 6 | 2021 | 47 | 1.120 |
Why?
|
| United States | 18 | 2021 | 1765 | 1.080 |
Why?
|
| Cohort Studies | 19 | 2023 | 1417 | 1.070 |
Why?
|
| Mental Status and Dementia Tests | 4 | 2021 | 42 | 1.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 147 | 1.000 |
Why?
|
| Depressive Disorder | 5 | 2017 | 163 | 0.990 |
Why?
|
| Memory | 10 | 2021 | 213 | 0.990 |
Why?
|
| Apolipoproteins E | 4 | 2023 | 142 | 0.970 |
Why?
|
| Depressive Disorder, Major | 9 | 2018 | 88 | 0.970 |
Why?
|
| Nerve Fibers, Myelinated | 5 | 2013 | 25 | 0.960 |
Why?
|
| Tryptophan | 5 | 2014 | 10 | 0.950 |
Why?
|
| Exercise | 7 | 2022 | 392 | 0.930 |
Why?
|
| Cross-Sectional Studies | 14 | 2023 | 760 | 0.920 |
Why?
|
| Stroke | 5 | 2023 | 241 | 0.920 |
Why?
|
| Cognitive Aging | 3 | 2020 | 56 | 0.910 |
Why?
|
| Hippocampus | 9 | 2022 | 198 | 0.900 |
Why?
|
| Educational Status | 5 | 2023 | 209 | 0.880 |
Why?
|
| Psychomotor Performance | 9 | 2020 | 155 | 0.870 |
Why?
|
| Adult | 28 | 2023 | 6923 | 0.850 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 105 | 0.840 |
Why?
|
| Pattern Recognition, Visual | 2 | 2019 | 13 | 0.830 |
Why?
|
| Linear Models | 6 | 2020 | 193 | 0.820 |
Why?
|
| Spatial Processing | 2 | 2021 | 4 | 0.800 |
Why?
|
| Mental Recall | 7 | 2020 | 49 | 0.780 |
Why?
|
| Genotype | 5 | 2020 | 248 | 0.780 |
Why?
|
| Income | 3 | 2021 | 63 | 0.780 |
Why?
|
| Social Participation | 1 | 2022 | 10 | 0.750 |
Why?
|
| Crime Victims | 1 | 2022 | 23 | 0.740 |
Why?
|
| Blood Glucose | 2 | 2022 | 99 | 0.740 |
Why?
|
| Longitudinal Studies | 13 | 2023 | 1046 | 0.740 |
Why?
|
| Leukoaraiosis | 3 | 2012 | 8 | 0.740 |
Why?
|
| Analysis of Variance | 10 | 2017 | 228 | 0.730 |
Why?
|
| Clinical Protocols | 1 | 2022 | 52 | 0.720 |
Why?
|
| Anisotropy | 5 | 2023 | 35 | 0.710 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2018 | 147 | 0.710 |
Why?
|
| Cerebral Cortex | 4 | 2021 | 125 | 0.710 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 37 | 0.700 |
Why?
|
| Psychology | 1 | 2021 | 15 | 0.690 |
Why?
|
| Optimism | 1 | 2021 | 1 | 0.680 |
Why?
|
| Family Relations | 1 | 2021 | 12 | 0.680 |
Why?
|
| Antihypertensive Agents | 2 | 2020 | 40 | 0.670 |
Why?
|
| Social Environment | 1 | 2021 | 66 | 0.670 |
Why?
|
| Social Segregation | 1 | 2020 | 6 | 0.660 |
Why?
|
| Racism | 1 | 2021 | 24 | 0.660 |
Why?
|
| Loneliness | 1 | 2021 | 42 | 0.660 |
Why?
|
| Dementia, Vascular | 5 | 2020 | 36 | 0.660 |
Why?
|
| Cholesterol | 2 | 2019 | 57 | 0.640 |
Why?
|
| Social Capital | 1 | 2020 | 2 | 0.640 |
Why?
|
| Social Support | 1 | 2021 | 174 | 0.620 |
Why?
|
| Life Style | 1 | 2021 | 159 | 0.620 |
Why?
|
| Prospective Studies | 13 | 2022 | 1493 | 0.620 |
Why?
|
| Dyslipidemias | 1 | 2019 | 15 | 0.620 |
Why?
|
| Triglycerides | 1 | 2019 | 54 | 0.620 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 35 | 0.610 |
Why?
|
| Independent Living | 6 | 2022 | 225 | 0.600 |
Why?
|
| Hyperinsulinism | 1 | 2019 | 4 | 0.600 |
Why?
|
| Stress, Psychological | 1 | 2021 | 206 | 0.600 |
Why?
|
| Mental Processes | 1 | 2019 | 15 | 0.590 |
Why?
|
| Cultural Diversity | 1 | 2019 | 20 | 0.590 |
Why?
|
| Neural Pathways | 9 | 2018 | 54 | 0.580 |
Why?
|
| Community Health Services | 1 | 2019 | 27 | 0.580 |
Why?
|
| Insulin Resistance | 1 | 2019 | 48 | 0.580 |
Why?
|
| Phenotype | 2 | 2019 | 260 | 0.580 |
Why?
|
| Multilingualism | 1 | 2019 | 19 | 0.580 |
Why?
|
| Kidney | 1 | 2019 | 142 | 0.570 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2023 | 138 | 0.560 |
Why?
|
| Psychological Trauma | 1 | 2017 | 2 | 0.540 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 260 | 0.530 |
Why?
|
| Affect | 3 | 2013 | 57 | 0.510 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 34 | 0.500 |
Why?
|
| Serotonin | 4 | 2014 | 22 | 0.500 |
Why?
|
| Individuality | 1 | 2016 | 15 | 0.490 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 7 | 0.450 |
Why?
|
| Psychomotor Disorders | 1 | 2014 | 9 | 0.440 |
Why?
|
| Thinking | 1 | 2014 | 12 | 0.440 |
Why?
|
| Verbal Behavior | 5 | 2009 | 13 | 0.440 |
Why?
|
| Age Factors | 8 | 2020 | 635 | 0.430 |
Why?
|
| Obesity | 4 | 2023 | 289 | 0.430 |
Why?
|
| Sex Factors | 6 | 2020 | 384 | 0.430 |
Why?
|
| Surveys and Questionnaires | 10 | 2021 | 1020 | 0.430 |
Why?
|
| Memory, Episodic | 3 | 2018 | 74 | 0.410 |
Why?
|
| Frontal Lobe | 5 | 2018 | 57 | 0.410 |
Why?
|
| Vascular Diseases | 2 | 2013 | 34 | 0.410 |
Why?
|
| Alleles | 5 | 2023 | 165 | 0.400 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2012 | 31 | 0.380 |
Why?
|
| Health Surveys | 4 | 2021 | 77 | 0.380 |
Why?
|
| Attention | 6 | 2023 | 101 | 0.380 |
Why?
|
| Models, Statistical | 3 | 2021 | 113 | 0.370 |
Why?
|
| Case-Control Studies | 9 | 2023 | 481 | 0.370 |
Why?
|
| Galvanic Skin Response | 1 | 2011 | 7 | 0.360 |
Why?
|
| Gambling | 1 | 2011 | 8 | 0.360 |
Why?
|
| Biomarkers | 4 | 2021 | 476 | 0.360 |
Why?
|
| Models, Psychological | 1 | 2011 | 58 | 0.350 |
Why?
|
| Dancing | 2 | 2021 | 10 | 0.350 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2023 | 124 | 0.350 |
Why?
|
| Down Syndrome | 1 | 2011 | 9 | 0.350 |
Why?
|
| Brain Chemistry | 1 | 2011 | 33 | 0.340 |
Why?
|
| Crime | 2 | 2021 | 6 | 0.330 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2016 | 153 | 0.330 |
Why?
|
| Sex Characteristics | 2 | 2022 | 85 | 0.320 |
Why?
|
| Chicago | 3 | 2021 | 813 | 0.320 |
Why?
|
| Basal Ganglia Cerebrovascular Disease | 1 | 2010 | 3 | 0.320 |
Why?
|
| Reaction Time | 6 | 2023 | 78 | 0.310 |
Why?
|
| Neural Inhibition | 2 | 2014 | 8 | 0.300 |
Why?
|
| Apolipoprotein E4 | 3 | 2020 | 172 | 0.300 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2017 | 267 | 0.290 |
Why?
|
| Myelin Sheath | 2 | 2021 | 22 | 0.270 |
Why?
|
| Young Adult | 7 | 2021 | 1651 | 0.270 |
Why?
|
| Amnesia | 5 | 2020 | 18 | 0.270 |
Why?
|
| Self Report | 3 | 2023 | 194 | 0.260 |
Why?
|
| Learning | 2 | 2018 | 59 | 0.260 |
Why?
|
| Hospitalization | 2 | 2019 | 286 | 0.260 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 592 | 0.250 |
Why?
|
| Visual Perception | 2 | 2020 | 21 | 0.250 |
Why?
|
| Language | 3 | 2021 | 57 | 0.250 |
Why?
|
| Principal Component Analysis | 3 | 2021 | 18 | 0.250 |
Why?
|
| Prevalence | 4 | 2021 | 375 | 0.250 |
Why?
|
| Nerve Net | 5 | 2018 | 34 | 0.250 |
Why?
|
| Pilot Projects | 3 | 2022 | 370 | 0.250 |
Why?
|
| DNA-Binding Proteins | 3 | 2023 | 228 | 0.240 |
Why?
|
| Problem Solving | 2 | 2009 | 38 | 0.230 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 801 | 0.220 |
Why?
|
| Temporal Lobe | 3 | 2018 | 58 | 0.220 |
Why?
|
| Discrimination Learning | 1 | 2004 | 1 | 0.210 |
Why?
|
| Color Perception | 1 | 2004 | 5 | 0.210 |
Why?
|
| Models, Neurological | 3 | 2018 | 19 | 0.210 |
Why?
|
| Arousal | 1 | 2004 | 48 | 0.210 |
Why?
|
| Time Factors | 2 | 2019 | 1262 | 0.210 |
Why?
|
| Adolescent | 6 | 2021 | 1881 | 0.200 |
Why?
|
| Autistic Disorder | 2 | 2014 | 38 | 0.200 |
Why?
|
| Postmenopause | 1 | 2023 | 57 | 0.200 |
Why?
|
| Research Design | 2 | 2021 | 157 | 0.200 |
Why?
|
| Intelligence Tests | 2 | 2015 | 13 | 0.190 |
Why?
|
| HIV Infections | 2 | 2021 | 431 | 0.190 |
Why?
|
| Psychometrics | 2 | 2021 | 176 | 0.190 |
Why?
|
| Fraud | 1 | 2022 | 16 | 0.190 |
Why?
|
| Atherosclerosis | 1 | 2023 | 44 | 0.190 |
Why?
|
| Geriatric Assessment | 3 | 2017 | 158 | 0.190 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 442 | 0.190 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 256 | 0.180 |
Why?
|
| Treatment Outcome | 2 | 2022 | 2941 | 0.180 |
Why?
|
| Regression Analysis | 5 | 2018 | 215 | 0.180 |
Why?
|
| Awareness | 1 | 2002 | 37 | 0.180 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2023 | 94 | 0.180 |
Why?
|
| Facial Expression | 2 | 2012 | 8 | 0.180 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 152 | 0.180 |
Why?
|
| Data Interpretation, Statistical | 3 | 2022 | 60 | 0.170 |
Why?
|
| Emotions | 2 | 2012 | 69 | 0.170 |
Why?
|
| Accelerometry | 2 | 2021 | 78 | 0.170 |
Why?
|
| Social Identification | 1 | 2021 | 6 | 0.170 |
Why?
|
| Social Networking | 1 | 2021 | 9 | 0.170 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2021 | 10 | 0.170 |
Why?
|
| Southeastern United States | 1 | 2020 | 13 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 243 | 0.170 |
Why?
|
| Midwestern United States | 1 | 2020 | 44 | 0.160 |
Why?
|
| Organ Size | 3 | 2023 | 87 | 0.160 |
Why?
|
| Mental Status Schedule | 3 | 2011 | 66 | 0.160 |
Why?
|
| Wechsler Scales | 3 | 2006 | 11 | 0.160 |
Why?
|
| Disabled Persons | 1 | 2021 | 86 | 0.160 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 1412 | 0.160 |
Why?
|
| Acute Disease | 2 | 2012 | 163 | 0.160 |
Why?
|
| Space Perception | 1 | 2020 | 19 | 0.160 |
Why?
|
| Judgment | 1 | 2019 | 4 | 0.160 |
Why?
|
| Patient Selection | 1 | 2021 | 167 | 0.160 |
Why?
|
| Pandemics | 1 | 2021 | 206 | 0.160 |
Why?
|
| Cholesterol, HDL | 1 | 2019 | 26 | 0.160 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 29 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 286 | 0.150 |
Why?
|
| Interpersonal Relations | 1 | 2020 | 86 | 0.150 |
Why?
|
| Hypercholesterolemia | 1 | 2019 | 20 | 0.150 |
Why?
|
| Atrophy | 2 | 2016 | 68 | 0.150 |
Why?
|
| Financing, Personal | 1 | 2018 | 16 | 0.150 |
Why?
|
| Cognitive Reserve | 1 | 2019 | 22 | 0.150 |
Why?
|
| Emergencies | 1 | 2019 | 28 | 0.150 |
Why?
|
| Genetic Variation | 1 | 2018 | 69 | 0.140 |
Why?
|
| Energy Intake | 1 | 2019 | 77 | 0.140 |
Why?
|
| Heterozygote | 1 | 2018 | 88 | 0.140 |
Why?
|
| Double-Blind Method | 3 | 2014 | 373 | 0.140 |
Why?
|
| Parkinson Disease | 2 | 2020 | 591 | 0.130 |
Why?
|
| Healthy Aging | 1 | 2017 | 8 | 0.130 |
Why?
|
| Healthy Lifestyle | 1 | 2017 | 36 | 0.130 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 96 | 0.130 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2016 | 15 | 0.130 |
Why?
|
| Motor Skills | 1 | 2017 | 37 | 0.130 |
Why?
|
| Phobia, Social | 1 | 2016 | 13 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 439 | 0.130 |
Why?
|
| Prognosis | 1 | 2019 | 730 | 0.120 |
Why?
|
| Self-Assessment | 2 | 2020 | 19 | 0.120 |
Why?
|
| Gyrus Cinguli | 2 | 2016 | 13 | 0.120 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 163 | 0.120 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 99 | 0.120 |
Why?
|
| Urban Population | 1 | 2017 | 127 | 0.120 |
Why?
|
| Cytokines | 1 | 2017 | 202 | 0.120 |
Why?
|
| Inflammation | 3 | 2023 | 231 | 0.110 |
Why?
|
| Cerebrovascular Circulation | 2 | 2014 | 28 | 0.110 |
Why?
|
| Macromolecular Substances | 1 | 2014 | 6 | 0.110 |
Why?
|
| Animals | 2 | 2013 | 3295 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2014 | 84 | 0.110 |
Why?
|
| Axons | 1 | 2013 | 24 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2016 | 219 | 0.100 |
Why?
|
| Oxygen | 1 | 2012 | 56 | 0.090 |
Why?
|
| Visual Cortex | 1 | 2012 | 4 | 0.090 |
Why?
|
| Auditory Cortex | 1 | 2012 | 3 | 0.090 |
Why?
|
| Language Tests | 2 | 2021 | 30 | 0.090 |
Why?
|
| Photic Stimulation | 3 | 2020 | 22 | 0.090 |
Why?
|
| Reward | 1 | 2011 | 18 | 0.090 |
Why?
|
| Task Performance and Analysis | 1 | 2011 | 43 | 0.090 |
Why?
|
| Social Class | 2 | 2022 | 55 | 0.090 |
Why?
|
| Inositol | 1 | 2011 | 5 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 32 | 0.090 |
Why?
|
| Aspartic Acid | 1 | 2011 | 12 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 523 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 4 | 0.080 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 8 | 0.080 |
Why?
|
| Antigen Presentation | 1 | 2010 | 14 | 0.080 |
Why?
|
| Syndrome | 1 | 2010 | 68 | 0.080 |
Why?
|
| Weight Loss | 2 | 2023 | 121 | 0.080 |
Why?
|
| Pain Measurement | 1 | 2011 | 412 | 0.080 |
Why?
|
| HIV-1 | 1 | 2010 | 203 | 0.070 |
Why?
|
| Medicare | 2 | 2019 | 106 | 0.070 |
Why?
|
| Neuropathology | 2 | 2019 | 59 | 0.070 |
Why?
|
| Cues | 2 | 2011 | 37 | 0.070 |
Why?
|
| Comorbidity | 1 | 2009 | 426 | 0.070 |
Why?
|
| Lewy Bodies | 2 | 2019 | 146 | 0.070 |
Why?
|
| Adaptation, Physiological | 1 | 2007 | 42 | 0.070 |
Why?
|
| Functional Laterality | 1 | 2007 | 54 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2011 | 39 | 0.070 |
Why?
|
| Reading | 1 | 2006 | 23 | 0.060 |
Why?
|
| Disease Progression | 2 | 2021 | 528 | 0.060 |
Why?
|
| Evoked Potentials | 1 | 2004 | 11 | 0.050 |
Why?
|
| Dominance, Cerebral | 1 | 2004 | 14 | 0.050 |
Why?
|
| Limbic System | 1 | 2004 | 7 | 0.050 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 64 | 0.050 |
Why?
|
| Reproduction | 1 | 2023 | 9 | 0.050 |
Why?
|
| Estrogens | 1 | 2023 | 26 | 0.050 |
Why?
|
| Baltimore | 1 | 2003 | 9 | 0.050 |
Why?
|
| Age of Onset | 2 | 2013 | 71 | 0.050 |
Why?
|
| Sample Size | 1 | 2003 | 17 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 39 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 25 | 0.050 |
Why?
|
| Infarction | 1 | 2023 | 19 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 169 | 0.050 |
Why?
|
| Maze Learning | 1 | 2002 | 12 | 0.050 |
Why?
|
| Pregnancy | 1 | 2023 | 324 | 0.050 |
Why?
|
| Physical Therapy Modalities | 1 | 2022 | 58 | 0.050 |
Why?
|
| Boston | 1 | 2022 | 13 | 0.050 |
Why?
|
| Cholinergic Antagonists | 1 | 2022 | 6 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 121 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2002 | 29 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2021 | 11 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 22 | 0.040 |
Why?
|
| Probability | 1 | 2021 | 71 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2021 | 42 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2021 | 11 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2020 | 2 | 0.040 |
Why?
|
| South America | 1 | 2020 | 3 | 0.040 |
Why?
|
| Lung | 1 | 2021 | 138 | 0.040 |
Why?
|
| Amino Acids | 2 | 2010 | 18 | 0.040 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2020 | 5 | 0.040 |
Why?
|
| New York | 1 | 2020 | 9 | 0.040 |
Why?
|
| Florida | 1 | 2020 | 15 | 0.040 |
Why?
|
| Walking | 1 | 2022 | 232 | 0.040 |
Why?
|
| California | 1 | 2020 | 35 | 0.040 |
Why?
|
| Orientation | 1 | 2020 | 5 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2019 | 12 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2020 | 44 | 0.040 |
Why?
|
| Cerebral Ventricles | 1 | 2019 | 16 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2019 | 22 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 311 | 0.040 |
Why?
|
| Lewy Body Disease | 1 | 2019 | 70 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 99 | 0.040 |
Why?
|
| Amyloid | 1 | 2018 | 37 | 0.040 |
Why?
|
| Amygdala | 1 | 2018 | 34 | 0.030 |
Why?
|
| Health Status | 1 | 2019 | 200 | 0.030 |
Why?
|
| Serial Learning | 1 | 2018 | 6 | 0.030 |
Why?
|
| Neurofibrillary Tangles | 1 | 2018 | 117 | 0.030 |
Why?
|
| Perception | 1 | 2018 | 64 | 0.030 |
Why?
|
| Comoros | 1 | 2017 | 1 | 0.030 |
Why?
|
| Autopsy | 1 | 2018 | 255 | 0.030 |
Why?
|
| tau Proteins | 1 | 2018 | 145 | 0.030 |
Why?
|
| Caloric Restriction | 1 | 2017 | 11 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 37 | 0.030 |
Why?
|
| Sphygmomanometers | 1 | 2017 | 2 | 0.030 |
Why?
|
| Massachusetts | 1 | 2017 | 16 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 70 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 165 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 378 | 0.030 |
Why?
|
| Czech Republic | 1 | 2014 | 1 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 23 | 0.030 |
Why?
|
| Thalamus | 1 | 2014 | 15 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2014 | 63 | 0.030 |
Why?
|
| Semantics | 1 | 2014 | 13 | 0.030 |
Why?
|
| Sensation | 1 | 2012 | 11 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 6 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 14 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 12 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 10 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 40 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 65 | 0.020 |
Why?
|
| Viral Load | 1 | 2010 | 70 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 72 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 79 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2010 | 55 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 168 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 351 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 111 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2009 | 218 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 67 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2011 | 2994 | 0.010 |
Why?
|